Literature DB >> 25139022

Tr-1-like CD4+CD25-CD127-/lowFOXP3- cells are the main source of interleukin 10 in patients with cutaneous leishmaniasis due to Leishmania braziliensis.

Diego L Costa1, Tiago M Cardoso2, Adriano Queiroz2, Cristiane M Milanezi1, Olívia Bacellar2, Edgar M Carvalho2, João S Silva1.   

Abstract

CD4(+)CD25(+)FOXP3(+) regulatory T cells have long been shown to mediate susceptibility to Leishmania infection, mainly via interleukin 10 production. In this work, we showed that the main sources of interleukin 10 in peripheral blood mononuclear cells (PBMCs) from patients with cutaneous leishmaniasis due to Leishmania braziliensis are CD4(+)CD25(-)CD127(-/low)FOXP3(-) cells. Compared with uninfected controls, patients with CL had increased frequencies of circulating interleukin 10-producing CD4(+)CD25(-)CD127(-/low) cells, which efficiently suppressed tumor necrosis factor α production by the total PBMC population. Also, in CL lesions, interleukin 10 was mainly produced by CD4(+)CD25(-) cells, and interleukin 10 messenger RNA expression was associated with interleukin 27, interleukin 21, and interferon γ expression, rather than with FOXP3 or transforming growth factor β expressions. Active production of both interleukin 27 and interleukin 21, together with production of interferon γ and interleukin 10, was also detected in the lesions. Since these cytokines are associated with the differentiation and activity of Tr-1 cells, our results suggest that this cell population may play an important role in the immunomodulation of CL. Therefore, development of treatments that interfere with this pathway may lead to faster parasite elimination.
© The Author 2014. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  IL-10; L. braziliensis; Tr-1 cells; tegumentary leishmaniasis

Mesh:

Substances:

Year:  2014        PMID: 25139022      PMCID: PMC4402371          DOI: 10.1093/infdis/jiu406

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  50 in total

Review 1.  Thymic and peripheral differentiation of regulatory T cells.

Authors:  Hyang-Mi Lee; Jhoanne Lynne Bautista; Chyi-Song Hsieh
Journal:  Adv Immunol       Date:  2011       Impact factor: 3.543

Review 2.  The immunobiology of IL-27.

Authors:  Aisling O'Hara Hall; Jonathan S Silver; Christopher A Hunter
Journal:  Adv Immunol       Date:  2012       Impact factor: 3.543

Review 3.  CD4+ Tregs and immune control.

Authors:  Zoltán Fehérvari; Shimon Sakaguchi
Journal:  J Clin Invest       Date:  2004-11       Impact factor: 14.808

4.  IL-10 neutralization promotes parasite clearance in splenic aspirate cells from patients with visceral leishmaniasis.

Authors:  Shalini Gautam; Rajiv Kumar; Radheshyam Maurya; Susanne Nylén; Nasim Ansari; Madhukar Rai; Shyam Sundar; David Sacks
Journal:  J Infect Dis       Date:  2011-10-01       Impact factor: 5.226

Review 5.  Leishmaniasis: complexity at the host-pathogen interface.

Authors:  Paul Kaye; Phillip Scott
Journal:  Nat Rev Microbiol       Date:  2011-07-11       Impact factor: 60.633

6.  Serial quantitative PCR assay for detection, species discrimination, and quantification of Leishmania spp. in human samples.

Authors:  Jason L Weirather; Selma M B Jeronimo; Shalini Gautam; Shyam Sundar; Mitchell Kang; Melissa A Kurtz; Rashidul Haque; Albert Schriefer; Sinésio Talhari; Edgar M Carvalho; John E Donelson; Mary E Wilson
Journal:  J Clin Microbiol       Date:  2011-11       Impact factor: 5.948

7.  Down-regulation of Th1 type of response in early human American cutaneous leishmaniasis.

Authors:  P N Rocha; R P Almeida; O Bacellar; A R de Jesus; D C Filho; A C Filho; A Barral; R L Coffman; E M Carvalho
Journal:  J Infect Dis       Date:  1999-11       Impact factor: 5.226

8.  Absence of gamma interferon and interleukin 2 production during active visceral leishmaniasis.

Authors:  E M Carvalho; R Badaró; S G Reed; T C Jones; W D Johnson
Journal:  J Clin Invest       Date:  1985-12       Impact factor: 14.808

9.  In vivo induction of Tr1 cells via mucosal dendritic cells and AHR signaling.

Authors:  Henry Yim Wu; Francisco J Quintana; Andre Pires da Cunha; Benjamin T Dake; Thomas Koeglsperger; Sarah C Starossom; Howard L Weiner
Journal:  PLoS One       Date:  2011-08-23       Impact factor: 3.240

10.  Cure of murine leishmaniasis with anti-interleukin 4 monoclonal antibody. Evidence for a T cell-dependent, interferon gamma-independent mechanism.

Authors:  M D Sadick; F P Heinzel; B J Holaday; R T Pu; R S Dawkins; R M Locksley
Journal:  J Exp Med       Date:  1990-01-01       Impact factor: 14.307

View more
  12 in total

1.  Role of IL-21 in host pathogenesis in experimental visceral leishmaniasis.

Authors:  R Khatonier; A M Khan; P Sarmah; G U Ahmed
Journal:  J Parasit Dis       Date:  2018-08-22

2.  Effector memory CD4(+) T cells differentially express activation associated molecules depending on the duration of American cutaneous leishmaniasis lesions.

Authors:  C de Oliveira Mendes-Aguiar; R Vieira-Gonçalves; L H Guimarães; M P de Oliveira-Neto; E M Carvalho; A M Da-Cruz
Journal:  Clin Exp Immunol       Date:  2016-06-06       Impact factor: 4.330

3.  Early Cutaneous Leishmaniasis Patients Infected With Leishmania braziliensis Express Increased Inflammatory Responses After Antimony Therapy.

Authors:  Rúbia S Costa; Lucas P Carvalho; Taís M Campos; Andréa S Magalhães; Sara T Passos; Albert Schriefer; Juliana A Silva; Ednaldo Lago; Camilla S Paixão; Paulo Machado; Phillip Scott; Edgar M Carvalho
Journal:  J Infect Dis       Date:  2018-02-14       Impact factor: 5.226

Review 4.  Cutaneous leishmaniasis: immune responses in protection and pathogenesis.

Authors:  Phillip Scott; Fernanda O Novais
Journal:  Nat Rev Immunol       Date:  2016-07-18       Impact factor: 53.106

5.  Development of real-time PCR assays for evaluation of immune response and parasite load in golden hamster (Mesocricetus auratus) infected by Leishmania (Viannia) braziliensis.

Authors:  Raquel Peralva Ribeiro-Romão; Andrea Franco Saavedra; Alda Maria Da-Cruz; Eduardo Fonseca Pinto; Otacilio C Moreira
Journal:  Parasit Vectors       Date:  2016-06-27       Impact factor: 3.876

6.  Interleukin-27 Early Impacts Leishmania infantum Infection in Mice and Correlates with Active Visceral Disease in Humans.

Authors:  Begoña Pérez-Cabezas; Pedro Cecílio; Ana Luisa Robalo; Ricardo Silvestre; Eugenia Carrillo; Javier Moreno; Juan V San Martín; Rita Vasconcellos; Anabela Cordeiro-da-Silva
Journal:  Front Immunol       Date:  2016-11-04       Impact factor: 7.561

7.  Leishmania braziliensis Infection Enhances Toll-Like Receptors 2 and 4 Expression and Triggers TNF-α and IL-10 Production in Human Cutaneous Leishmaniasis.

Authors:  Ludmila P Polari; Pedro Paulo Carneiro; Michael Macedo; Paulo R L Machado; Phillip Scott; Edgar M Carvalho; Olívia Bacellar
Journal:  Front Cell Infect Microbiol       Date:  2019-05-02       Impact factor: 6.073

8.  Evaluation of Regulatory Immune Response in Skin Lesions of Patients Affected by Nonulcerated or Atypical Cutaneous Leishmaniasis in Honduras, Central America.

Authors:  Gabriela Venicia Araujo Flores; Carmen Maria Sandoval Pacheco; Thaise Yumie Tomokane; Wilfredo Sosa Ochoa; Concepción Zúniga Valeriano; Claudia Maria Castro Gomes; Carlos Eduardo Pereira Corbett; Marcia Dalastra Laurenti
Journal:  Mediators Inflamm       Date:  2018-03-21       Impact factor: 4.711

Review 9.  Interleukin-27 Functional Duality Balances Leishmania Infectivity and Pathogenesis.

Authors:  Abdollah Jafarzadeh; Maryam Nemati; Prashant Chauhan; Ashok Patidar; Arup Sarkar; Iraj Sharifi; Bhaskar Saha
Journal:  Front Immunol       Date:  2020-08-07       Impact factor: 7.561

Review 10.  Interleukin (IL)-21 in Inflammation and Immunity During Parasitic Diseases.

Authors:  Shahram Solaymani-Mohammadi; Lars Eckmann; Steven M Singer
Journal:  Front Cell Infect Microbiol       Date:  2019-12-04       Impact factor: 5.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.